ARWR
Price
$15.05
Change
-$0.15 (-0.99%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
2.07B
57 days until earnings call
DNLI
Price
$15.04
Change
+$0.09 (+0.60%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
2.18B
62 days until earnings call
Ad is loading...

ARWR vs DNLI

Header iconARWR vs DNLI Comparison
Open Charts ARWR vs DNLIBanner chart's image
Arrowhead Pharmaceuticals
Price$15.05
Change-$0.15 (-0.99%)
Volume$47.16K
Capitalization2.07B
Denali Therapeutics
Price$15.04
Change+$0.09 (+0.60%)
Volume$24.36K
Capitalization2.18B
ARWR vs DNLI Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. DNLI commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (ARWR: $15.22 vs. DNLI: $14.95)
Brand notoriety: ARWR: Notable vs. DNLI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 104% vs. DNLI: 155%
Market capitalization -- ARWR: $2.07B vs. DNLI: $2.18B
ARWR [@Biotechnology] is valued at $2.07B. DNLI’s [@Biotechnology] market capitalization is $2.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 6 bearish.
  • DNLI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ARWR and DNLI are a bad buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а -14.06% price change this week, while DNLI (@Biotechnology) price change was -1.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.64%. For the same industry, the average monthly price growth was -8.11%, and the average quarterly price growth was -7.39%.

Reported Earning Dates

ARWR is expected to report earnings on May 08, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+0.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.18B) has a higher market cap than ARWR($2.07B). ARWR YTD gains are higher at: -19.043 vs. DNLI (-26.644). DNLI has higher annual earnings (EBITDA): -496.05M vs. ARWR (-561.51M). DNLI has more cash in the bank: 837M vs. ARWR (681M). DNLI has less debt than ARWR: DNLI (52.5M) vs ARWR (511M). ARWR has higher revenues than DNLI: ARWR (3.55M) vs DNLI (0).
ARWRDNLIARWR / DNLI
Capitalization2.07B2.18B95%
EBITDA-561.51M-496.05M113%
Gain YTD-19.043-26.64471%
P/E RatioN/AN/A-
Revenue3.55M0-
Total Cash681M837M81%
Total Debt511M52.5M973%
FUNDAMENTALS RATINGS
ARWR vs DNLI: Fundamental Ratings
ARWR
DNLI
OUTLOOK RATING
1..100
5558
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9991
PRICE GROWTH RATING
1..100
9791
P/E GROWTH RATING
1..100
297
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (94) in the Biotechnology industry is in the same range as ARWR (96). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's SMR Rating (91) in the Biotechnology industry is in the same range as ARWR (99). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

DNLI's Price Growth Rating (91) in the Biotechnology industry is in the same range as ARWR (97). This means that DNLI’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for DNLI (97). This means that ARWR’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CHTTX20.39N/A
N/A
AMG River Road Mid Cap Value N
RLUSX16.37N/A
N/A
Lazard US Equity Focus R6
WHGAX19.06N/A
N/A
Westwood Quality SmallCap Fund A
OARDX24.54N/A
N/A
Invesco Rising Dividends A
FSPSX53.11N/A
N/A
Fidelity International Index

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-10.31%
DNLI - ARWR
51%
Loosely correlated
-10.43%
NTLA - ARWR
49%
Loosely correlated
-8.60%
FATE - ARWR
47%
Loosely correlated
-8.24%
RGNX - ARWR
47%
Loosely correlated
-5.21%
ALNY - ARWR
46%
Loosely correlated
-4.64%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-10.43%
RCKT - DNLI
53%
Loosely correlated
-2.05%
RGNX - DNLI
52%
Loosely correlated
-5.21%
NTLA - DNLI
52%
Loosely correlated
-8.60%
BEAM - DNLI
52%
Loosely correlated
-9.80%
CRSP - DNLI
51%
Loosely correlated
-4.81%
More